- Home
- AKBA vs MFA Comparison
AKBA vs MFA Comparison
Compare AKBA & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- MFA
- Stock Information
- Founded
- AKBA 2007
- MFA 1997
- Country
- AKBA United States
- MFA United States
- Employees
- AKBA N/A
- MFA N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- MFA Real Estate Investment Trusts
- Sector
- AKBA Health Care
- MFA Real Estate
- Exchange
- AKBA Nasdaq
- MFA Nasdaq
- Market Cap
- AKBA 958.6M
- MFA 980.3M
- IPO Year
- AKBA 2014
- MFA N/A
- Fundamental
- Price
- AKBA $3.42
- MFA $9.32
- Analyst Decision
- AKBA Strong Buy
- MFA Buy
- Analyst Count
- AKBA 5
- MFA 9
- Target Price
- AKBA $6.90
- MFA $11.75
- AVG Volume (30 Days)
- AKBA 3.8M
- MFA 1.3M
- Earning Date
- AKBA 08-07-2025
- MFA 08-06-2025
- Dividend Yield
- AKBA N/A
- MFA 15.47%
- EPS Growth
- AKBA N/A
- MFA 41.64
- EPS
- AKBA N/A
- MFA 0.88
- Revenue
- AKBA $203,733,000.00
- MFA $284,489,000.00
- Revenue This Year
- AKBA $27.95
- MFA N/A
- Revenue Next Year
- AKBA $43.88
- MFA $12.27
- P/E Ratio
- AKBA N/A
- MFA $10.58
- Revenue Growth
- AKBA 16.75
- MFA 9.37
- 52 Week Low
- AKBA $1.07
- MFA $7.85
- 52 Week High
- AKBA $4.08
- MFA $13.45
- Technical
- Relative Strength Index (RSI)
- AKBA 44.17
- MFA 48.61
- Support Level
- AKBA $2.92
- MFA $8.78
- Resistance Level
- AKBA $3.79
- MFA $9.47
- Average True Range (ATR)
- AKBA 0.20
- MFA 0.19
- MACD
- AKBA -0.06
- MFA 0.00
- Stochastic Oscillator
- AKBA 44.64
- MFA 70.39
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.